European Radiology:深度学习,让冠状动脉CT血管造影实现“双减”!

2022-03-09 shaosai MedSci原创

现阶段,冠状动脉CTA(CCTA)已被确立为疑似阻塞性冠心病(CAD)患者的一线无创成像方式之一。

现阶段冠状动脉CTA(CCTA)已被确立为疑似阻塞性冠心病(CAD)患者的一线无创成像方式之一。SCOUT-HEART研究的结果表明,与单纯的标准治疗相比,在疑似CAD的标准治疗基础上增加CCTA检查在5年内降低CAD死亡或非致命性心肌梗死(MI)的发生率方面具有优势,这无疑增强了CCTA的应用价值

尽管CCTA在病变检测方面具有极大优势,但人们对辐射的担忧仍然存在。此外,造影剂引起的肾病(CIN)仍然是这些患者的潜在风险。此外,利用新的先进技术(即CT-FFR)进行CCTA的进一步成像后处理、狭窄评估和准确的功能预测都需要依靠理想的原始图像质量。因此,如何在尽可能低的辐射和造影剂剂量下获得优秀的图像质量引起了巨大的研究兴趣。在CT中使用低电压(在70或80kVp)是实现 "双低(低辐射和对比)"剂量目标的最有效方法之一。然而,传统上,低电压的使用仅限于瘦小的病人(BMI<23 kg/m2),并且由于低能量X射线的穿透力降低,会进一步增加图像的噪声。以前的研究报告称,与传统的ASIR-V相比,用深度学习图像重建(DLIR)算法降低CCTA图像噪声的能力更高。然而,DLIR在平衡图像噪声、空间分辨率和图像外观方面的优越性是否在较低的管电压下保持,仍然是未知数。

近日,发表在European Radiology杂志的一项研究评估70-kvp管电压和高强度设置的DLIR算法(DLIR-H)组合在CCTA检查中的表现,为实现"双低"剂量目标提供了技术支持

本研究前瞻性地招募了100名进行CCTA检查的患者,并随机分为两组:低剂量组(n = 50),70 kVp,Smart mA的噪音指数(NI)为36HU,对比剂剂量率为16mgI/kg/s,DLIR-H;常规组(n = 50),120 kV,Smart mA的NI为25HU,对比剂剂量率为32mgI/kg/s,60%ASIR-V。比较了两组之间辐射和对比剂剂量、主观图像质量评分和客观图像质量测量(图像噪声、对比度-噪声比(CNR)和血管的信号-噪声比(SNR))。 

与传统组(分别为48.23±6.38 mL和1.65±0.66 mSv)相比,低剂量组使用的造影剂剂量(23.82±3.69 mL,减少50.6%)和辐射剂量(0.75±0.14 mSv,减少54.5%)明显减少(所有P<0.001)。然而,与传统组相比,低剂量组的背景噪音更低(23.57 ± 4.74 HU vs. 35.04 ± 8.41 HU),RCA(48.63 ± 10.76 vs. 29.32 ± 5.52)、LAD(47.33 ± 10.20 vs. 29.27 ± 5.12)和LCX(46.74 ± 9.76 vs. 28.58 ± 5.12)的CNR更高(所有p < 0.001)。 

 

 低剂量组和常规剂量组的图像质量比较。A1-A4,低剂量组的病例。男性,54岁,BMI为25.61kg/m2,采用70-kvp方案扫描以及高强度深度学习图像重建算法进行重建。图像质量达到主观评分5分,血管边界清晰,图像噪声为12.6 HU;B1-B4,常规剂量组病例。男性,57岁,BMI为25.53 kg/m2,用120-kvp方案扫描以及统计迭代重建算法进行重建。图像质量达到主观评分4分,血管边界有些模糊,图像噪声为17.7H。两位患者均显示冠状动脉正常,但低剂量组的图像质量明显更好。

总之,与传统的120kVp和ASIR-V方案相比,结合70kVp管电压和DLIR-H算法的 "双低 "剂量CCTA方案可显著降低辐射剂量造影剂剂量的同时,为正常体型的患者提供更高的图像质量。

原文出处

Wanjiang Li,Kaiyue Diao,Yuting Wen,et al.High-strength deep learning image reconstruction in coronary CT angiography at 70-kVp tube voltage significantly improves image quality and reduces both radiation and contrast doses.DOI:10.1007/s00330-021-08424-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708796, encodeId=654b1e0879601, content=<a href='/topic/show?id=989d308399f' target=_blank style='color:#2F92EE;'>#冠状动脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30839, encryptionId=989d308399f, topicName=冠状动脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b7b31562840, createdName=1249897bm47(暂无昵称), createdTime=Mon Jul 11 07:41:23 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993940, encodeId=ab981993940d0, content=<a href='/topic/show?id=01473084099' target=_blank style='color:#2F92EE;'>#冠状动脉CT血管造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30840, encryptionId=01473084099, topicName=冠状动脉CT血管造影)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Sep 14 07:41:23 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729408, encodeId=9fe41e2940882, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 15 13:41:23 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494201, encodeId=c5be1494201a9, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Fri Mar 11 00:41:23 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708796, encodeId=654b1e0879601, content=<a href='/topic/show?id=989d308399f' target=_blank style='color:#2F92EE;'>#冠状动脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30839, encryptionId=989d308399f, topicName=冠状动脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b7b31562840, createdName=1249897bm47(暂无昵称), createdTime=Mon Jul 11 07:41:23 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993940, encodeId=ab981993940d0, content=<a href='/topic/show?id=01473084099' target=_blank style='color:#2F92EE;'>#冠状动脉CT血管造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30840, encryptionId=01473084099, topicName=冠状动脉CT血管造影)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Sep 14 07:41:23 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729408, encodeId=9fe41e2940882, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 15 13:41:23 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494201, encodeId=c5be1494201a9, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Fri Mar 11 00:41:23 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708796, encodeId=654b1e0879601, content=<a href='/topic/show?id=989d308399f' target=_blank style='color:#2F92EE;'>#冠状动脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30839, encryptionId=989d308399f, topicName=冠状动脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b7b31562840, createdName=1249897bm47(暂无昵称), createdTime=Mon Jul 11 07:41:23 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993940, encodeId=ab981993940d0, content=<a href='/topic/show?id=01473084099' target=_blank style='color:#2F92EE;'>#冠状动脉CT血管造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30840, encryptionId=01473084099, topicName=冠状动脉CT血管造影)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Sep 14 07:41:23 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729408, encodeId=9fe41e2940882, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 15 13:41:23 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494201, encodeId=c5be1494201a9, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Fri Mar 11 00:41:23 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-11-15 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708796, encodeId=654b1e0879601, content=<a href='/topic/show?id=989d308399f' target=_blank style='color:#2F92EE;'>#冠状动脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30839, encryptionId=989d308399f, topicName=冠状动脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b7b31562840, createdName=1249897bm47(暂无昵称), createdTime=Mon Jul 11 07:41:23 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993940, encodeId=ab981993940d0, content=<a href='/topic/show?id=01473084099' target=_blank style='color:#2F92EE;'>#冠状动脉CT血管造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30840, encryptionId=01473084099, topicName=冠状动脉CT血管造影)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Sep 14 07:41:23 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729408, encodeId=9fe41e2940882, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 15 13:41:23 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494201, encodeId=c5be1494201a9, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Fri Mar 11 00:41:23 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 sodoo

相关资讯

J Hepatol:非酒精性脂肪性肝病与亚临床冠状动脉粥样硬化之间的相关性

在无症状的个体中,非酒精性脂肪肝(NAFLD)是非钙化斑块的独立危险因子,被称为与突发和意外心脏事件相关的易损斑块。因此,NAFLD需要适当的药物治疗,以减少未来的心脏事件。

European Radiology:CCTA的左房功能是心衰和心血管死亡的预测因子

尽管最近心脏病的治疗效果有所改善,但心力衰竭(HF)仍然是一种预后极差的常见疾病。越来越多的证据表明,左心房(LA)重构和功能障碍可能作为疾病进展的调节因素和症状发展的预测因素而发挥重要作用。

陈韵岱:CCTA临床适用推荐及循证支持

作为诊断冠状动脉性心脏病的影像学工具,冠状动脉CT成像(CCTA)已经成为最主要的无创手段之一。尤其在当今“无影像,不干预”的时代背景下,CCTA的临床适应证也不断得到更新。大量文献显示CCTA诊断冠状动脉疾病的准确性极佳,可以评估有症状的中危冠心病患者的冠脉情况,这对于心内科医生的临床诊断流程和治疗相关路径又提出了新的要求。下面就CCTA在临床尤其对心内科常见病的适用标准及循证支持展开简要论

SCCT 2014:CCTA预测冠脉疾病患者生存或更佳

心血管CT学会(SCCT)2014年会的一项报告表明,与接受心肌单光子发射体层摄影(SPECT)检查的可疑冠脉疾病患者相比,冠状动脉CT血管造影(CCTA)检查者在随访期间生存率较高和无因心梗所致住院的可能性更大。 此项回顾性研究对25000例接受CCAT或心肌SPECT检查患者的资料进行了评估,并排除了同时接受CCAT和SPECT检查的患者。剩余患者分别有7376和4467例接受CCAT和SP

European Radiology:严重钙化的冠脉究竟要如何评估狭窄程度?CTA有了新办法!

冠状动脉计算机断层扫描(CCTA)是检测冠状动脉狭窄的首选无创影像学检查。然而,对于有严重钙化斑块的节段,CCTA的诊断准确性十分有限。